Top Key Companies for CAR-T Cell Immunotherapy Market: Genscript Biotech Corporation, Celgene Corporation, Mustang Bio, Inc., Aurora Biopharma Inc., Pfizer, Inc., CARsgen Therapeutics, Ltd., Sorrento Therapeutics Inc., Novartis International AG, Gilead Sciences, Inc..
Global CAR-T Cell Immunotherapy Market Research Report: 2023-2030 Outlook with Market Insights, Industry and Competitive Analysis Included. Remarkable growth trajectory projected.
Global CAR-T Cell Immunotherapy Market Overview And Scope:
The Global CAR-T Cell Immunotherapy Market Report 2023 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of CAR-T Cell Immunotherapy utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2023 and 2030. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global CAR-T Cell Immunotherapy Market Segmentation
By Type, CAR-T Cell Immunotherapy market has been segmented into:
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16
L1CAM
ROR1
EGFRvIII
PSCA
NKR-2
IL13Ra2
LewisY)
By Application, CAR-T Cell Immunotherapy market has been segmented into:
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
Regional Analysis of CAR-T Cell Immunotherapy Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of CAR-T Cell Immunotherapy Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The CAR-T Cell Immunotherapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the CAR-T Cell Immunotherapy market.
Top Key Companies Covered in CAR-T Cell Immunotherapy market are:
Genscript Biotech Corporation
Celgene Corporation
Mustang Bio
Inc.
Aurora Biopharma Inc.
Pfizer
Inc.
CARsgen Therapeutics
Ltd.
Sorrento Therapeutics Inc.
Novartis International AG
Gilead Sciences
Inc.
Key Questions answered in the CAR-T Cell Immunotherapy Market Report:
1. What is the expected CAR-T Cell Immunotherapy Market size during the forecast period, 2022-2028?
2. Which region is the largest market for the CAR-T Cell Immunotherapy Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the CAR-T Cell Immunotherapy Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the CAR-T Cell Immunotherapy Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key CAR-T Cell Immunotherapy companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the CAR-T Cell Immunotherapy Markets?
7. How is the funding and investment landscape in the CAR-T Cell Immunotherapy Market?
8. Which are the leading consortiums and associations in the CAR-T Cell Immunotherapy Market, and what is their role in the market?
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: CAR-T Cell Immunotherapy Market by Type
5.1 CAR-T Cell Immunotherapy Market Overview Snapshot and Growth Engine
5.2 CAR-T Cell Immunotherapy Market Overview
5.3 CD19/CD22
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2030F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 CD19/CD22: Geographic Segmentation
5.4 BCMA (B-Cell Maturation Antigen)
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2030F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 BCMA (B-Cell Maturation Antigen): Geographic Segmentation
5.5 Others (MUC16
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2030F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others (MUC16: Geographic Segmentation
5.6 L1CAM
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2016-2030F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 L1CAM: Geographic Segmentation
5.7 ROR1
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2016-2030F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 ROR1: Geographic Segmentation
5.8 EGFRvIII
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2016-2030F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 EGFRvIII: Geographic Segmentation
5.9 PSCA
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size (2016-2030F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 PSCA: Geographic Segmentation
5.10 NKR-2
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size (2016-2030F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 NKR-2: Geographic Segmentation
5.11 IL13Ra2
5.11.1 Introduction and Market Overview
5.11.2 Historic and Forecasted Market Size (2016-2030F)
5.11.3 Key Market Trends, Growth Factors and Opportunities
5.11.4 IL13Ra2: Geographic Segmentation
5.12 LewisY)
5.12.1 Introduction and Market Overview
5.12.2 Historic and Forecasted Market Size (2016-2030F)
5.12.3 Key Market Trends, Growth Factors and Opportunities
5.12.4 LewisY): Geographic Segmentation
Chapter 6: CAR-T Cell Immunotherapy Market by Application
6.1 CAR-T Cell Immunotherapy Market Overview Snapshot and Growth Engine
6.2 CAR-T Cell Immunotherapy Market Overview
6.3 Diffuse Large B-Cell Lymphoma (DLBCL)
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2030F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Diffuse Large B-Cell Lymphoma (DLBCL): Geographic Segmentation
6.4 Acute Lymphoblastic Leukemia (ALL)
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2030F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Acute Lymphoblastic Leukemia (ALL): Geographic Segmentation
6.5 Chronic Lymphocytic Leukemia (CLL)
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2030F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Chronic Lymphocytic Leukemia (CLL): Geographic Segmentation
6.6 Multiple Myeloma (MM)
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2030F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Multiple Myeloma (MM): Geographic Segmentation
6.7 Follicular Lymphoma (FL)
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2016-2030F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Follicular Lymphoma (FL): Geographic Segmentation
6.8 Others
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2016-2030F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 CAR-T Cell Immunotherapy Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 CAR-T Cell Immunotherapy Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 CAR-T Cell Immunotherapy Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 GENSCRIPT BIOTECH CORPORATION
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CELGENE CORPORATION
7.4 MUSTANG BIO
7.5 INC.
7.6 AURORA BIOPHARMA INC.
7.7 PFIZER
7.8 INC.
7.9 CARSGEN THERAPEUTICS
7.10 LTD.
7.11 SORRENTO THERAPEUTICS INC.
7.12 NOVARTIS INTERNATIONAL AG
7.13 GILEAD SCIENCES
7.14 INC.
Chapter 8: Global CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 CD19/CD22
8.2.2 BCMA (B-Cell Maturation Antigen)
8.2.3 Others (MUC16
8.2.4 L1CAM
8.2.5 ROR1
8.2.6 EGFRvIII
8.2.7 PSCA
8.2.8 NKR-2
8.2.9 IL13Ra2
8.2.10 LewisY)
8.3 Historic and Forecasted Market Size By Application
8.3.1 Diffuse Large B-Cell Lymphoma (DLBCL)
8.3.2 Acute Lymphoblastic Leukemia (ALL)
8.3.3 Chronic Lymphocytic Leukemia (CLL)
8.3.4 Multiple Myeloma (MM)
8.3.5 Follicular Lymphoma (FL)
8.3.6 Others
Chapter 9: North America CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 CD19/CD22
9.4.2 BCMA (B-Cell Maturation Antigen)
9.4.3 Others (MUC16
9.4.4 L1CAM
9.4.5 ROR1
9.4.6 EGFRvIII
9.4.7 PSCA
9.4.8 NKR-2
9.4.9 IL13Ra2
9.4.10 LewisY)
9.5 Historic and Forecasted Market Size By Application
9.5.1 Diffuse Large B-Cell Lymphoma (DLBCL)
9.5.2 Acute Lymphoblastic Leukemia (ALL)
9.5.3 Chronic Lymphocytic Leukemia (CLL)
9.5.4 Multiple Myeloma (MM)
9.5.5 Follicular Lymphoma (FL)
9.5.6 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 CD19/CD22
10.4.2 BCMA (B-Cell Maturation Antigen)
10.4.3 Others (MUC16
10.4.4 L1CAM
10.4.5 ROR1
10.4.6 EGFRvIII
10.4.7 PSCA
10.4.8 NKR-2
10.4.9 IL13Ra2
10.4.10 LewisY)
10.5 Historic and Forecasted Market Size By Application
10.5.1 Diffuse Large B-Cell Lymphoma (DLBCL)
10.5.2 Acute Lymphoblastic Leukemia (ALL)
10.5.3 Chronic Lymphocytic Leukemia (CLL)
10.5.4 Multiple Myeloma (MM)
10.5.5 Follicular Lymphoma (FL)
10.5.6 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 CD19/CD22
11.4.2 BCMA (B-Cell Maturation Antigen)
11.4.3 Others (MUC16
11.4.4 L1CAM
11.4.5 ROR1
11.4.6 EGFRvIII
11.4.7 PSCA
11.4.8 NKR-2
11.4.9 IL13Ra2
11.4.10 LewisY)
11.5 Historic and Forecasted Market Size By Application
11.5.1 Diffuse Large B-Cell Lymphoma (DLBCL)
11.5.2 Acute Lymphoblastic Leukemia (ALL)
11.5.3 Chronic Lymphocytic Leukemia (CLL)
11.5.4 Multiple Myeloma (MM)
11.5.5 Follicular Lymphoma (FL)
11.5.6 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 CD19/CD22
12.4.2 BCMA (B-Cell Maturation Antigen)
12.4.3 Others (MUC16
12.4.4 L1CAM
12.4.5 ROR1
12.4.6 EGFRvIII
12.4.7 PSCA
12.4.8 NKR-2
12.4.9 IL13Ra2
12.4.10 LewisY)
12.5 Historic and Forecasted Market Size By Application
12.5.1 Diffuse Large B-Cell Lymphoma (DLBCL)
12.5.2 Acute Lymphoblastic Leukemia (ALL)
12.5.3 Chronic Lymphocytic Leukemia (CLL)
12.5.4 Multiple Myeloma (MM)
12.5.5 Follicular Lymphoma (FL)
12.5.6 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 CD19/CD22
13.4.2 BCMA (B-Cell Maturation Antigen)
13.4.3 Others (MUC16
13.4.4 L1CAM
13.4.5 ROR1
13.4.6 EGFRvIII
13.4.7 PSCA
13.4.8 NKR-2
13.4.9 IL13Ra2
13.4.10 LewisY)
13.5 Historic and Forecasted Market Size By Application
13.5.1 Diffuse Large B-Cell Lymphoma (DLBCL)
13.5.2 Acute Lymphoblastic Leukemia (ALL)
13.5.3 Chronic Lymphocytic Leukemia (CLL)
13.5.4 Multiple Myeloma (MM)
13.5.5 Follicular Lymphoma (FL)
13.5.6 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America CAR-T Cell Immunotherapy Market Analysis, Insights and Forecast, 2016-2030
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 CD19/CD22
14.4.2 BCMA (B-Cell Maturation Antigen)
14.4.3 Others (MUC16
14.4.4 L1CAM
14.4.5 ROR1
14.4.6 EGFRvIII
14.4.7 PSCA
14.4.8 NKR-2
14.4.9 IL13Ra2
14.4.10 LewisY)
14.5 Historic and Forecasted Market Size By Application
14.5.1 Diffuse Large B-Cell Lymphoma (DLBCL)
14.5.2 Acute Lymphoblastic Leukemia (ALL)
14.5.3 Chronic Lymphocytic Leukemia (CLL)
14.5.4 Multiple Myeloma (MM)
14.5.5 Follicular Lymphoma (FL)
14.5.6 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
CAR-T Cell Immunotherapy Scope:
|
Report Data
|
CAR-T Cell Immunotherapy Market
|
|
CAR-T Cell Immunotherapy Market Size in 2022
|
USD XXX million
|
|
CAR-T Cell Immunotherapy CAGR 2023 - 2030
|
XX%
|
|
CAR-T Cell Immunotherapy Base Year
|
2022
|
|
CAR-T Cell Immunotherapy Forecast Data
|
2023 - 2030
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Genscript Biotech Corporation, Celgene Corporation, Mustang Bio, Inc., Aurora Biopharma Inc., Pfizer, Inc., CARsgen Therapeutics, Ltd., Sorrento Therapeutics Inc., Novartis International AG, Gilead Sciences, Inc..
|
|
Key Segments
|
By Type
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16
L1CAM
ROR1
EGFRvIII
PSCA
NKR-2
IL13Ra2
LewisY)
By Applications
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
|
